HDAC2 Inhibitor Discovery: Cellular Assay and In Vivo Efficacy Data

Naoyuki Suzuki published a dataset on figshare in March 2026 detailing the discovery of selective HDAC2 inhibitors for Alzheimer's disease. The data, stored in a 1 KB CSV file, originates from a high-throughput screening campaign using novel cellular assays to identify compounds that elevate histone acetylation in vivo without hematologic toxicity. The dataset includes results for hit compounds, including the optimized compound 11, which showed significant in vivo efficacy.

Use Cases

• Train ML models to predict HDAC2 selectivity based on cellular assay results mentioned in the description.
• Analyze structure-activity relationships for compounds balancing cellular potency and BCRP recognition.
• Validate in silico screening methods against experimental data for HDAC isoform selectivity.
• Compare the in vivo efficacy profile of compound 11 with other HDAC inhibitors in preclinical research.

Strengths

• Data is associated with a specific, peer-reviewed research goal: discovering selective HDAC2 inhibitors.
• The dataset includes results for at least two identified compounds (6 and 11) with detailed in vivo and toxicity profiles.
• Published under a clear CC-BY-NC-4.0 license, specifying terms for reuse.

Limitations

• The dataset is extremely small at 1 KB, suggesting limited scope or a summary of results.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for statistical modeling.

Provenance

Source

figshare, authored by Naoyuki Suzuki.

Collection Method

Likely contains experimental results from high-throughput screening and in vivo testing.

Freshness

Last updated 2026-03-18 02:30:27; freshness should be verified.